CUE Cue Biopharma
Company Analysis
Latest News
Cue Biopharma Gets Strong Sell Downgrade from Wall Street Zen
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from sell to strong sell in a research note issued Saturday. The downgrade followed a volatile week for...
🔴 Cue Biopharma is trading 5.3% down today with no clear company-specific catalyst identified
Cue Biopharma is trading 5.3% down at $31.11 during live trading on September 25, 2026, with no clear company-specific catalyst identified. - Its latest major...
🟢 Cue Biopharma is trading 9.98% up today in pre-market after CUE-221 met Phase 2 primary endpoint
Cue Biopharma is trading 9.98% up now at $36.13 as investors continue reacting to positive September 20 topline Phase 2 results for CUE-221. - The study met...
🟢 Cue Biopharma is trading 5.3% up today after statistically significant CUE-221 Phase 2 efficacy results
Cue Biopharma is trading at $33.39, up 5.30%, rebounding after positive CUE-221 Phase 2 results announced September 20, which showed statistically significant...
🔴 Cue Biopharma is trading 2% down in pre-market as broader market weakness pressures biotech shares
Cue Biopharma is trading 2% down at $31.10 as broader U.S. market weakness pressures risk-sensitive biotechnology shares. - The Nasdaq Composite is down 0.86%...
🔴 Cue Biopharma is trading 5.39% down today in after-hours trading as U.S. markets weakened
Cue Biopharma is trading 5.39% lower at $30.00 in after-hours trading as broader U.S. markets weakened. - On September 23, 2026, the S&P 500 fell 0.73% and the...
Cue Biopharma's Allergy Drug Aces a Key Trial — But Can a 29-Person Company Turn Clinic Wins Into a Billion-Dollar Franchise?
Shares surged as Cue Biopharma's experimental anti-allergy treatment delivered the kind of clinical data that transforms tiny biotechs overnight. The...
🟢 Cue Biopharma is trading 11.3% up today after CUE-221 Phase 2 met key endpoints
Cue Biopharma is trading 11.33% higher at $34.40 as investors continue reacting to positive CUE-221 Phase 2 results announced September 20, 2026. - The study...
🟢 Cue Biopharma is trading 5% up today after Phase 2 study met endpoints
Cue Biopharma is trading 5% higher at $32.48, amid continued volatility following the September 20 CUE-221 Phase 2 results and broader biotech strength. - The...
🔴 Cue Biopharma is trading 5.6% down in pre-market with no identified late-breaking catalyst
Cue Biopharma is trading 5.6% lower at $29.16 in pre-market on September 23, 2026, with no new company-specific announcement or reliable late-breaking catalyst...
🔴 Cue Biopharma is trading 5.3% down in after-hours trading
Cue Biopharma is trading 5.34% down at $29.25 now, with no identified company-specific announcement or reliable late-breaking catalyst explaining the...
🔴 Cue Biopharma is trading 5.1% down today
Cue Biopharma is trading 5.1% down at $26.82 after a highly volatile session, with no new company-specific announcement or reliable catalyst identified for...
🟢 Cue Biopharma is trading 11.21% up today — no reliable catalyst identified
Cue Biopharma is trading 11.21% up at $31.44, with no reliable company-specific announcement or overnight catalyst identified for the September 22 rebound. -...
🔴 Cue Biopharma is trading 5.6% down in pre-market — no reliable overnight catalyst reported
Cue Biopharma is trading 5.55% down at $26.70, with no reliable overnight announcement explaining the additional pre-market decline. - Shares fell 23.70%...
🔴 Cue Biopharma is trading 6.32% down today despite positive Phase 2 CUE-221 results
Cue Biopharma is trading 6.32% down at $34.71 after opening-market selling on September 21, 2026; no reliable source identifies a specific negative...
Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Urticaria
Cue Biopharma announced positive topline results from a Phase 2 clinical trial of its drug candidate, CUE-221, for the treatment of Chronic Spontaneous...
🟢 Cue Biopharma is trading 40.69% up in pre-market after CUE-221 achieved 54% complete hive resolution
Cue Biopharma is trading 40.69% up at $52.13 after positive Phase 2 results for CUE-221 in chronic spontaneous urticaria. • The highest dose produced 54%...
Cue Biopharma Hives Drug Hits Phase 2 Goals, Showing 54% Resolution
Cue Biopharma reported positive topline results from a Phase 2 trial of CUE-221 for moderate to severe chronic spontaneous urticaria (CSU). The study involved...
B. Riley Slaps an $83 Target on Cue Biopharma at $40 — Can a Single Drug Candidate Justify Doubling the Stock?
Shares of Cue Biopharma surged as much as 7.9% to $39.99 on September 19 after B. Riley Securities launched coverage with a Buy rating and an $83 price target...
🟢 Cue Biopharma is trading 7.94% up in after-hours trading after B. Riley initiated coverage with a Buy rating
Cue Biopharma is trading 7.94% up at $39.99 in after-hours trading after B. Riley initiated coverage with a Buy rating on September 18, 2026. - B. Riley set...